Add 2 More Reports For 20% off

Report Overview

The hepatic disease treatment market was valued at USD 24.78 billion in 2023, driven by the rising prevalence of liver diseases across the 8 major markets. It is further expected to grow at a CAGR of about 6.2% in the forecast period of 2024-2032 to reach a value of around USD 42.50 billion by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Hepatic Disease Treatment Market Outlook

  • The rising cases of liver diseases such as hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cancer are likely to augment the market demand for innovative treatments. 
  • Increased funding and grants for research and development of hepatic disease treatments is a major trend that is poised to result in the introduction of more effective drugs with better safety profiles.
  • The market value is influenced by improvements in diagnostic techniques, heightened public awareness, and advancements in antiviral therapies.

Hepatic Disease Treatment Market Overview

Hepatic disease refers to various disorders that impair or prevent the liver from functioning properly. Yellowing of the skin or eyes (jaundice), abdominal pain, or abnormal liver function test results may indicate liver illness. Common liver ailments include cancer, hepatitis, autoimmune diseases, and genetic problems. 

The rise in the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. The high burden of liver disease is propelling the demand for the hepatic disease treatment market. One of the primary factors augmenting the market growth is the increasing geriatric population, which is susceptible to a variety of chronic diseases, including liver disease. Moreover, the quick acceptance of antiviral medications, which are safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favorably influencing the market growth.

Further, increasing research and development activities, significant growth in the healthcare industry, and implementation of various government initiatives in order to promote public health are creating a positive outlook for the hepatic disease treatment market value. For instance, the Indian government announced the integration of non-alcoholic fatty liver disease (NAFLD) with the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). This program is mainly focused on early diagnosis and management of NAFLD, along with building healthcare infrastructure for the prevention, diagnosis, and treatment of NAFLD. Additionally, the development of novel therapeutics and advancements in diagnostic techniques are some of the factors aiding the market expansion.

Hepatic Disease Treatment Market Growth Drivers

Increasing Prevalence of Liver Diseases to Affect the Market Landscape Significantly

Recent studies reveal that liver disease is responsible for 2 million deaths every year and accounts for 4% of all deaths worldwide (1 in every 25 deaths). It is reported that roughly two-thirds of all liver-related deaths occur in males. Liver cancer also poses a significant health challenge, causing 600,000 to 900,000 deaths annually, primarily as a result of cirrhosis and hepatocellular carcinoma . According to the American Cancer Society, the year 2024 will witness the diagnosis of around 41,630 individuals with primary liver cancer and intrahepatic bile duct cancer in the United States. Further, it is also estimated that 29,840 individuals will die from these cancers , indicating the need for effective medications to combat this liver disease. Thus, the rising burden of liver diseases is set to bolster the growth and innovation in the market.

Hepatic Disease Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Key Trends Impact
Advancements in Diagnostic Technologies One of the major market trends is the rising improvements in diagnostic technologies such as imaging techniques (MRI, CT scans) and biomarker-based tests. These advancements help in the early and accurate diagnosis of liver diseases.
Increased Investment in R&D Increased funding and grants for research and development of hepatic disease treatments by the government and healthcare organizations is a major market trend. This investment is expected to accelerate the discovery and commercialization of new and effective therapies, which is anticipated to boost the hepatic disease treatment market value.
Growing Regulatory Support The market benefits from the presence of a favorable regulatory environment, with regulatory bodies offering orphan drug designations and incentives for novel therapies that are designed to treat rare liver diseases. In addition, the implementation of fast-track and accelerated approval processes is anticipated to support market expansion in the forecast period.
Heightened Public Awareness The market is witnessing heightened public awareness regarding liver diseases and their treatments which is prompting more individuals to seek medical attention. This trend is supported by rising public health campaigns and education programs aimed at highlighting the importance of early intervention and adherence to treatment protocols.

Hepatic Disease Treatment Market Segmentation

Market Breakup by Treatment Type

  • Antiviral Drugs
  • Monoclonal Antibodies
  • Immunosuppressants Drugs
  • Vaccines
  • Corticosteroids Drugs
  • Targeted Therapy
  • Others

Market Breakup by Disease Type

  • Hepatitis
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Hepatic Cancer
  • Other

Market Breakup by Route of Administration

  • Parenteral
  • Oral
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Hepatic Disease Treatment Market Share

The Antiviral Drugs Segment Based on Treatment Type is Anticipated to Witness Substantial Growth

Based on the treatment type, the market is segmented into antiviral drugs, monoclonal antibodies, immunosuppressant drugs, vaccines, corticosteroid drugs, targeted therapy, and others. The antiviral drugs segment holds a high market value which can be attributed to the high prevalence of viral hepatitis such as hepatitis B and C which can result in chronic liver diseases, cirrhosis, and liver cancer. The chronic nature of these hepatic diseases drives the need for long-term antiviral treatment.

Hepatic Disease Treatment Market Analysis by Region

The United States represents a major market for hepatic disease treatment owing to the high prevalence of liver diseases including hepatitis B and C. According to the Centers for Disease Control and Prevention, roughly 800,000 to 1.4 million Americans have chronic hepatitis B virus (HBV) infection, and hepatitis B is the underlying cause of 2,000 to 4,000 fatalities in the United States each year. The increasing number of cases of such liver diseases propels the demand for effective treatments and therapeutics in the region. India is also projected to have substantial market growth in the forecast period owing to improvements in healthcare infrastructure, rising spending on healthcare services, and increased government funds and grants for research and development of hepatic disease treatments.

Leading Players in the Hepatic Disease Treatment Market

The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AbbVie Inc.

American pharmaceutical company AbbVie is a major market player and invests heavily in R&D to develop innovative therapies for hepatic diseases. The company is known for its combination therapies to treat chronic hepatitis C virus (HCV) infection such as its FDA-approved combination drug MAVYRET  (glecaprevir/pibrentasvir).

Merck & Co., Inc.

United States-based Merck & Co., focuses on developing novel treatments for liver diseases, including both antivirals and vaccines. The company is also involved in health initiatives aimed at eliminating hepatitis.

F. Hoffmann-La Roche Ltd

Swiss multinational holding healthcare company Roche is engaged in advancing its pipeline of hepatic disease treatments. Its drug Pegasys (peginterferon alfa-2a) is often used in combination with other antiviral medications to treat chronic hepatitis B and C infections.

Eli Lilly and Company

Headquartered in Indiana (United States), pharmaceutical giant Eli Lilly and Company is one of the key players in the market. It is focused on developing treatments that target liver cancer and fibrosis.
Other key players in the market include Bristol-Myers Squibb Company, Gilead Sciences, Inc., Novartis AG, Takeda Pharmaceuticals Company Ltd., Otsuka Holdings, and GSK PLC.

Key Questions Answered in the Hepatic Disease Treatment Market Report

  • What was the hepatic disease treatment market value in 2023?
  • What is the hepatic disease treatment market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on the treatment type?
  • What is the market breakup based on the disease type?
  • What is the market breakup by route of administration?
  • What are the major factors aiding the hepatic disease treatment market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How do the prevalence and incidence of hepatic diseases affect the market landscape?
  • What are the major hepatic disease treatment market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which treatment type will dominate the market share? 
  • Which disease type is expected to have a high market value in the coming years?
  • Which route of administration will experience the highest demand in the market segment?
  • Who are the key players involved in the hepatic disease treatment market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment Type
  • Disease Type
  • Route of Administration
  • Region
Breakup by Treatment Type
  • Antiviral Drugs
  • Monoclonal Antibodies
  • Immunosuppressants Drugs
  • Vaccines
  • Corticosteroids Drugs
  • Targeted Therapy
  • Others
Breakup by Disease Type
  • Hepatitis
  • Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Hepatic Cancer
  • Other
Breakup by Route of Administration
  •  Parenteral
  • Oral
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • AbbVie Inc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Novartis AG
  • Takeda Pharmaceuticals Company Ltd.
  • Gilead Science, Inc.
  • Otsuka Holdings
  • GSK PLC.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124